Treatment Clinical Trials for Non-Small Cell Lung Cancer
Clinical trials are research studies that involve people. The clinical trials on this list are for non-small cell lung cancer treatment. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Epacadostat and Sirolimus in Treating Participants with Advanced Cancer
This phase I trial studies the side effects and best dose of epacadostat and sirolimus in treating participants with cancer that has spread to other places in the. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as sirolimus, is used to decrease the body’s immune response and may increase blood cell count. Giving epacadostat and sirolimus may work better at treating advanced cancer.
Location: 6 locations
Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back. Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 295 locations
Pulsed Low Dose Radiation Therapy and Chemotherapy in Reducing the Rates of Severe Acute Esophagitis in Patients with Stage IIIA Non-small Cell Lung Cancer and Stage IB-IIIC Esophageal Cancer
This phase I trial studies how well pulsed low dose radiation therapy and chemotherapy work in reducing the rates of severe acute esophagitis in patients with stage IIIA non-small cell lung cancer and stage IB-IIIC esophageal cancer. Pulsed low dose rate radiation therapy uses short pulses to deliver low doses of radiation for extended times and may reduce the rate of severe acute esophagitis in patients with lung and esophageal cancer.
Location: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Human Chimeric Antigen Receptor Modified T-Cells with or without Cyclophosphamide in Treating Patients with Mesothelin-Expressing Cancers
This phase I trial studies the side effects of human chimeric antigen receptor modified T-cells (huCART-meso cells) with or without cyclophosphamide in treating patients with mesothelin-expressing cancers. T-cells or white blood cells can be genetically modified by introducing a receptor called a chimeric antigen receptor (CAR) that recognizes mesothelin protein. Using huCART-meso cells can help identify cancerous cells and may improve the body's ability to fight mesothelin-expressing cancers. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether huCART-meso cells with or without cyclophosphamide work better in treating patients with mesothelin-expressing cancers.
Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania
Pembrolizumab and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Melanoma or Non-small Cell Lung Cancer
This phase Ib / IIa trial studies the side effects and best dose of stereotactic body radiation therapy when given together with pembrolizumab in treating patients with melanoma or non-small cell lung cancer that has spread to other places in the body. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Monoclonal antibodies, such as pembrolizumab, may block specific proteins which may strengthen the immune system and control tumor growth. Giving stereotactic body radiation therapy may prolong the response to pembrolizumab in patients with melanoma or non-small cell lung cancer.
Location: Yale University, New Haven, Connecticut
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Background: During recent years, cancer-testis (CT) antigens (CTA), particularly those encoded by genes on the X chromosome (CT-X genes), have emerged as attractive targets for cancer immunotherapy. Whereas malignancies of diverse histologies express a variety of CTAs, immune responses to these proteins appear uncommon in cancer patients, possibly due to low-level, heterogeneous antigen expression, as well as immunosuppressive regulatory T cells present within tumor sites and systemic circulation of these individuals. Conceivably, vaccination of cancer patients with tumor cells expressing high levels of CTAs in combination with regimens that deplete or inhibit T regulatory cells will induce broad immunity to these antigens. In order to examine this issue, patients with primary lung and esophageal cancers, pleural mesotheliomas, thoracic sarcomas, thymic neoplasms and mediastinal germ cell tumors, as well as sarcomas, melanomas, germ cell tumors, or epithelial malignancies metastatic to lungs, pleura or mediastinum with no evidence of disease (NED) or minimal residual disease (MRD) following standard multidisciplinary therapy will be vaccinated with H1299 tumor cell lysates with Iscomatrix adjuvant. Vaccines will be administered with or without metronomic oral cyclophosphamide (50 mg PO BID x 7d q 14d), and celecoxib (400 mg PO BID). Serologic responses to a variety of recombinant CTAs as well as immunologic responses to autologous tumor or epigenetically modified autologous EBVtransformed lymphocytes will be assessed before and after a six month vaccination period. Primary Objectives: 1. To assess the frequency of immunologic responses to CTAs in patients with thoracic malignancies following vaccinations with H1299 cell lysate / Iscomatrix(TM) vaccines alone in comparison to patients with thoracic malignancies following vaccinations with H1299 cell lysate / Iscomatrix vaccines in combination with metronomic cyclophosphamide and celecoxib. Secondary Objectives: 1. To examine if oral metronomic cyclophosphamide and celecoxib therapy diminishes the number and percentage of T regulatory cells and diminishes activity of these cells in patients with thoracic malignancies are at risk of recurrence. 2. To examine if H1299 cell lysate / Iscomatrix(TM) vaccination enhances immunologic response to autologous tumor or epigenetically modified autologous EBV-transformed lymphocytes (B cells). Eligibility: - Patients with histologically or cytologically proven small cell or non-small cell lung cancer (SCLC;NSCLC), esophageal cancer (EsC), malignant pleural mesothelioma (MPM) , thymic or mediastinal germ cell tumors, thoracic sarcomas, or melanomas, sarcomas, or epithelial malignancies metastatic to lungs, pleura or mediastinum who have no clinical evidence of active disease (NED), or minimal residual disease (MRD) not readily accessible by non-invasive biopsy or resection / radiation following standard therapy completed within the past 26 weeks. - Patients must be 18 years or older with an ECOG performance status of 0 2. - Patients must have adequate bone marrow, kidney, liver, lung and cardiac function. - Patients may not be on systemic immunosuppressive medications at time vaccinations commence. Design: - Following recovery from surgery, chemotherapy, or chemo / XRT, patients with NED or MRD will be vaccinated via IM injection with H1299 cell lysates and Iscomatrix(TM) adjuvant monthly for 6 months. - Vaccines will be administered with or without with metronomic oral cyclophosphamide and celecoxib. - Systemic toxicities and immunologic response to therapy will be recorded. Pre and post vaccination serologic and cell mediated responses to a standard panel of CT antigens as well as autologous tumor cells (if available) and EBV-transformed lymphocytes will be assessed before and after vaccination. - Numbers / percentages and function of T regulatory cells in peripheral blood will be assessed before, during, and after vaccinations. - Patients will be followed in the clinic with routine staging scans until disease recurrence. - The trial will randomize 28 evaluable patients per arm to either receive vaccine alone or vaccine plus chemotherapy in order to have 80% power to determine if the frequency of immune responses on the combination arm exceeds that of the vaccine alone arm, if the expected frequencies of immune responses on the two arms were 20% and 50%, using a one-sided 0.10 alpha level Fisher s exact
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients with Stage II-IIIB Non-small Cell Lung Cancer
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab together with paclitaxel, carboplatin, and radiation therapy may kill more tumor cells.
Location: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients with Advanced Melanoma, Lung, or Kidney Cancer
This phase II trial studies how well image guided hypofractionated radiation therapy works with nelfinavir mesylate, pembrolizumab, nivolumab, and atezolizumab in treating patients with melanoma, lung cancer, or kidney cancer that has spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, nivolumab and atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving hypofractionated radiation therapy, nelfinavir mesylate, pembrolizumab, nivolumab and atezolizumab may work better in treating patients with melanoma, lung, or kidney cancer.
Location: See Clinical Trials.gov